source
- Biogen CEO says company will pause new acquisitions and focus on developing existing pipelineBiogen's chief executive Christopher Viehbacher told analysts during the second-quarter earnings call that the company will slow its merger and acquisition activity for the foreseeable future. Aft…
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…BioPharma Dive · 9d ago↗ source